Highlights Fresh Tracks Therapeutics, Inc.

Equities

FRTX

US10802T2042

Market Closed - OTC Markets Other stock markets 03:58:44 2024-05-16 pm EDT			5-day change	1st Jan Change
0.9335 ^USD	+3.71%		+1.46%	+6.19%

Mar. 15	Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Fresh Tracks Therapeutics' Board Approves Liquidation Plan; Shares Rise After Hours	23-09-19	MT
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Earnings Flash (BBI) FRESH TRACKS THERAPEUTICS Posts Q1 Revenue $9,000	23-05-10	MT
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Earnings Flash (BBI) FRESH TRACKS THERAPEUTICS Posts Q4 Revenue $2.1M	23-03-30	MT
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-30	CI
Fresh Tracks Therapeutics, Inc. Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02	23-03-07	CI
Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02	23-01-11	CI
Earnings Flash (BBI) FRESH TRACKS THERAPEUTICS Posts Q3 Revenue $0.5M	22-11-10	MT
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of Dyrk1a Inhibitor FRTX-02	22-09-13	CI
Brickell Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Brickell Biotech Regains Compliance With Nasdaq's Minimum Bid Price Requirement for Continued Listing	22-07-20	MT
Reverse Split: 1 of 45	22-07-04	FA
Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02	22-05-19	CI
Brickell Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Earnings Flash (BBI) BRICKELL BIOTECH Posts Q1 Revenue $92,000	22-05-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Fresh Tracks Therapeutics, Inc.

Equities

FRTX

US10802T2042

Highlights

Filters